Neurocrine (0K6R) AI Stock Analysis

Neurocrine

(LSE:0K6R)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High-margin profitabilityNeurocrine combines sustained revenue expansion with exceptionally high gross profitability and improving net and operating margins. This creates substantial earnings leverage, supports ongoing investment in commercial and pipeline programs, and provides a durable foundation for cash generation.

Negative Factors

Decelerating growthAlthough revenue remains positive, the marked slowdown from earlier expansion raises the importance of successful product launches and pipeline execution. Lower underlying growth can reduce operating leverage over time and make future earnings increasingly dependent on a smaller number of key programs.

Neurocrine (0K6R) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $14.85B
Dividend Yield: ―
Average Volume (3M): 1,117
Price to Earnings (P/E): 20.7
Beta (1Y): 0.53
Revenue Growth: 34.42%
EPS Growth: 102.44%
Country: UK
Employees: 2,500
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Neurocrine Business Overview & Revenue Model

Company Description

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and market...

Neurocrine Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:-18.55%|Next Earnings Date:Nov 01, 2026

Earnings Call SentimentPositive

The call conveyed strong commercial execution and significant growth: near-record quarterly sales, raised INGREZZA guidance, sustained CRENESSITY launch momentum, immediate accretion from the VYKAT XR acquisition, and a deep pipeline with material Phase 3 catalysts in 2027. Key negatives are near-term GAAP headwinds and cash use from the ~$2.9B acquisition, early-stage launch variability and discontinuations for VYKAT XR, and lingering policy/pipeline outcome uncertainties that could create EPS variability. Overall, the positive operational and pipeline developments outweigh the transitional and financial integration challenges.

Positive Updates

Record Quarterly Revenue and Strong YoY Growth

Total revenue exceeded $950 million in Q2 FY26, representing nearly 40% year-over-year growth; pro forma total revenues (including a full quarter of VYKAT XR) were $998 million.

Negative Updates

Acquisition-Related Charges and GAAP Impact

Soleno acquisition (~$2.9 billion) generated approximately $150 million of expected acquisition-related costs (about $130 million recognized in Q2) plus noncash purchase accounting amortization and inventory step-up of ~ $20 million in Q2, which weigh on GAAP results.

Company Guidance

Management raised full‑year INGREZZA guidance to $2.825–$2.875 billion (midpoint ≈13% YoY) after a Q2 in which total revenue topped $950M (nearly 40% YoY) and non‑GAAP EPS was $2.85; Q2 product results included INGREZZA $716M (+15% YoY), CRENESSITY $184M (≈15% of estimated diagnosed CAH patients now treated), and pro forma VYKAT XR $94M (Neurocrine recognized $54M since the May 18 close), producing pro forma Q2 revenues of $998M and combined quarterly sales approaching $1B (annualizing ≈$4B). The company completed the Soleno acquisition for ~$2.9B financed with cash, ended Q2 with ~$500M cash and no debt, updated operating expense guidance to include Soleno operating, transaction and integration costs, and expects ~ $150M of acquisition‑related costs in 2026 (≈$130M recognized in Q2) plus ~ $20M of GAAP purchase accounting amortization; management also expects sequential VYKAT XR growth exiting 2026 and remains on track for multiple Phase 3 readouts in H2 2027.

Neurocrine Risk Analysis

Neurocrine disclosed 51 risk factors in its most recent earnings report. Neurocrine reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Our credit facility imposes operating and financial restrictions on us, and our failure to comply with its covenants or satisfy our obligations under the facility could adversely affect our business and financial condition.Q2, 2026

2.Future acquisitions could disrupt our business and harm our financial condition.Q2, 2026

3.We may not successfully integrate Soleno or realize the anticipated benefits of the acquisition, which could adversely affect our business and financial condition.Q2, 2026

Neurocrine Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0K6R against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	76Outperform	$2.26B	12.38	20.06%	―	24.25%	-0.83%
ACAD	73Outperform	$3.55B	9.15	32.39%	―	11.75%	68.42%
PRAX	63Neutral	$7.98B	-22.08	-34.15%	―	-100.00%	-5.32%
XENE	60Neutral	$3.62B	-7.89	-43.98%	―	-100.00%	-33.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AXSM	47Neutral	$7.57B	-38.51	-255.60%	―	56.87%	25.87%

* Healthcare Sector Average

Performance Comparison

GB:0K6R and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0K6R	Neurocrine Biosciences	146.74	5.12	3.61%
ACAD	ACADIA Pharmaceuticals Inc.	20.59	-1.78	-7.96%
XENE	Xenon Pharmaceuticals	37.41	-3.71	-9.02%
AXSM	Axsome Therapeutics Inc.	144.43	8.68	6.39%
HRMY	Harmony Biosciences Holdings, Inc.	38.76	9.43	32.15%
PRAX	Praxis Precision Medicines, Inc.	285.93	103.94	57.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Neurocrine AI Stock Analysis